Cargando…

Development and validation of a clinical and genetic model for predicting risk of severe COVID-19

Clinical and genetic risk factors for severe coronavirus disease 2019 (COVID-19) are often considered independently and without knowledge of the magnitudes of their effects on risk. Using severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) positive participants from the UK Biobank, we devel...

Descripción completa

Detalles Bibliográficos
Autores principales: Dite, Gillian S., Murphy, Nicholas M., Allman, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292840/
https://www.ncbi.nlm.nih.gov/pubmed/34210368
http://dx.doi.org/10.1017/S095026882100145X
_version_ 1783724904757067776
author Dite, Gillian S.
Murphy, Nicholas M.
Allman, Richard
author_facet Dite, Gillian S.
Murphy, Nicholas M.
Allman, Richard
author_sort Dite, Gillian S.
collection PubMed
description Clinical and genetic risk factors for severe coronavirus disease 2019 (COVID-19) are often considered independently and without knowledge of the magnitudes of their effects on risk. Using severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) positive participants from the UK Biobank, we developed and validated a clinical and genetic model to predict risk of severe COVID-19. We used multivariable logistic regression on a 70% training dataset and used the remaining 30% for validation. We also validated a previously published prototype model. In the validation dataset, our new model was associated with severe COVID-19 (odds ratio per quintile of risk = 1.77, 95% confidence interval (CI) 1.64–1.90) and had acceptable discrimination (area under the receiver operating characteristic curve = 0.732, 95% CI 0.708–0.756). We assessed calibration using logistic regression of the log odds of the risk score, and the new model showed no evidence of over- or under-estimation of risk (α = −0.08; 95% CI −0.21−0.05) and no evidence or over-or under-dispersion of risk (β = 0.90, 95% CI 0.80–1.00). Accurate prediction of individual risk is possible and will be important in regions where vaccines are not widely available or where people refuse or are disqualified from vaccination, especially given uncertainty about the extent of infection transmission among vaccinated people and the emergence of SARS-CoV-2 variants of concern.
format Online
Article
Text
id pubmed-8292840
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-82928402021-07-21 Development and validation of a clinical and genetic model for predicting risk of severe COVID-19 Dite, Gillian S. Murphy, Nicholas M. Allman, Richard Epidemiol Infect Original Paper Clinical and genetic risk factors for severe coronavirus disease 2019 (COVID-19) are often considered independently and without knowledge of the magnitudes of their effects on risk. Using severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) positive participants from the UK Biobank, we developed and validated a clinical and genetic model to predict risk of severe COVID-19. We used multivariable logistic regression on a 70% training dataset and used the remaining 30% for validation. We also validated a previously published prototype model. In the validation dataset, our new model was associated with severe COVID-19 (odds ratio per quintile of risk = 1.77, 95% confidence interval (CI) 1.64–1.90) and had acceptable discrimination (area under the receiver operating characteristic curve = 0.732, 95% CI 0.708–0.756). We assessed calibration using logistic regression of the log odds of the risk score, and the new model showed no evidence of over- or under-estimation of risk (α = −0.08; 95% CI −0.21−0.05) and no evidence or over-or under-dispersion of risk (β = 0.90, 95% CI 0.80–1.00). Accurate prediction of individual risk is possible and will be important in regions where vaccines are not widely available or where people refuse or are disqualified from vaccination, especially given uncertainty about the extent of infection transmission among vaccinated people and the emergence of SARS-CoV-2 variants of concern. Cambridge University Press 2021-07-02 /pmc/articles/PMC8292840/ /pubmed/34210368 http://dx.doi.org/10.1017/S095026882100145X Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
spellingShingle Original Paper
Dite, Gillian S.
Murphy, Nicholas M.
Allman, Richard
Development and validation of a clinical and genetic model for predicting risk of severe COVID-19
title Development and validation of a clinical and genetic model for predicting risk of severe COVID-19
title_full Development and validation of a clinical and genetic model for predicting risk of severe COVID-19
title_fullStr Development and validation of a clinical and genetic model for predicting risk of severe COVID-19
title_full_unstemmed Development and validation of a clinical and genetic model for predicting risk of severe COVID-19
title_short Development and validation of a clinical and genetic model for predicting risk of severe COVID-19
title_sort development and validation of a clinical and genetic model for predicting risk of severe covid-19
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292840/
https://www.ncbi.nlm.nih.gov/pubmed/34210368
http://dx.doi.org/10.1017/S095026882100145X
work_keys_str_mv AT ditegillians developmentandvalidationofaclinicalandgeneticmodelforpredictingriskofseverecovid19
AT murphynicholasm developmentandvalidationofaclinicalandgeneticmodelforpredictingriskofseverecovid19
AT allmanrichard developmentandvalidationofaclinicalandgeneticmodelforpredictingriskofseverecovid19